ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesChapter 2: NeoplasmsC25

C25

Billable

Malignant neoplasm of pancreas

Chapter 2:Neoplasms

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 C25 is a billable code used to indicate a diagnosis of malignant neoplasm of pancreas.

Key Diagnostic Point:

Malignant neoplasm of the pancreas, commonly referred to as pancreatic cancer, is a highly aggressive form of cancer that originates in the tissues of the pancreas. The pancreas is a vital organ responsible for producing digestive enzymes and hormones, including insulin. Pancreatic cancer often presents with vague symptoms, such as abdominal pain, weight loss, and jaundice, which can lead to late diagnosis. The disease is typically classified into exocrine tumors, which account for the majority of cases, and neuroendocrine tumors. Staging pancreatic cancer can be particularly challenging due to the lack of early symptoms and the tendency for the disease to metastasize quickly. The CA 19-9 tumor marker is often utilized in the diagnosis and monitoring of pancreatic cancer, although it is not exclusively specific to this condition. Unfortunately, the prognosis for patients diagnosed with pancreatic cancer is generally poor, with a five-year survival rate of less than 10%, primarily due to late-stage diagnosis and aggressive tumor behavior.

Code Complexity Analysis

Complexity Rating: High

High Complexity

Complexity Factors

  • Difficulty in staging due to late presentation of symptoms
  • Variability in tumor markers (e.g., CA 19-9) and their interpretation
  • Need for precise documentation of tumor type and stage
  • Potential for multiple metastatic sites complicating coding

Audit Risk Factors

  • Inadequate documentation of staging and tumor type
  • Failure to document CA 19-9 levels and their significance
  • Misclassification of tumor type (exocrine vs. neuroendocrine)
  • Lack of clarity in metastatic involvement

Specialty Focus

Medical Specialties

Oncology

Documentation Requirements

Detailed pathology reports, imaging studies, and treatment plans are essential for accurate coding.

Common Clinical Scenarios

Initial diagnosis, staging, treatment planning, and follow-up care.

Billing Considerations

Ensure accurate documentation of tumor markers and staging to support coding.

Gastroenterology

Documentation Requirements

Endoscopic reports, imaging results, and biopsy findings are critical.

Common Clinical Scenarios

Evaluation of abdominal pain, jaundice, and weight loss; management of complications.

Billing Considerations

Documenting the clinical rationale for imaging and lab tests is crucial.

Coding Guidelines

Inclusion Criteria

Use C25 When
  • Follow the official ICD
  • CM coding guidelines, ensuring accurate documentation of the tumor's location, type, and stage
  • Include any relevant lab results, such as CA 19
  • 9 levels, and document any metastatic sites

Exclusion Criteria

Do NOT use C25 When
No specific exclusions found.

Related CPT Codes

47562CPT Code

Laparoscopic cholecystectomy

Clinical Scenario

Often performed in patients with pancreatic cancer to manage biliary obstruction.

Documentation Requirements

Document indications for surgery and any complications.

Specialty Considerations

Ensure surgical notes are detailed and include findings.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of pancreatic cancer, improving the accuracy of data collection and reimbursement processes. The detailed coding structure helps in tracking treatment outcomes and resource utilization.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of pancreatic cancer, improving the accuracy of data collection and reimbursement processes. The detailed coding structure helps in tracking treatment outcomes and resource utilization.

Reimbursement & Billing Impact

reimbursement processes. The detailed coding structure helps in tracking treatment outcomes and resource utilization.

Resources

Clinical References

  • •
    American Cancer Society - Pancreatic Cancer

Coding & Billing References

  • •
    American Cancer Society - Pancreatic Cancer

Frequently Asked Questions

What is the significance of CA 19-9 in pancreatic cancer?

CA 19-9 is a tumor marker that can help in diagnosing pancreatic cancer and monitoring treatment response. Elevated levels may indicate the presence of cancer, but they are not definitive, as they can also be elevated in other conditions.